North America Leukemia Therapeutics Market, By Type (Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)), Treatment Type (Targeted Drugs and Immunotherapy, Chemotherapy), Molecule Type (Small Molecules, Biologics), Mode of Administration (Injectable, Oral), Gender (Male, Female), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
North America Leukemia Therapeutics Market Analysis and Size
Leukemia treatment is constantly emerging to cope with the rise in blood cancer cases. According to the Leukemia & Lymphoma Society 2021 study, men are affected by leukemia by a ratio of about 36.5%. Leukaemia prevalence varies among patients of different sexes, ages and races and these disparities are related mainly to environmental exposure levels. Additionally, the growing number of investments in research and development has allowed numerous pharmaceutical and biotechnology companies to primarily focus on and develop novel and effective drugs.
Data Bridge Market Research analyses a growth rate in the leukemia therapeutics market in the forecast period 2023-2030. The market is expected to reach USD 5.75 billion by 2030, which was USD 2.7 billion in 2022, is expected to undergo a CAGR of 9.9% from 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
North America Leukemia Therapeutics Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML)), Treatment Type (Targeted Drugs and Immunotherapy, Chemotherapy), Molecule Type (Small Molecules, Biologics), Mode of Administration (Injectable, Oral), Gender (Male, Female), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Cipla Inc. (U.S.), Abbott (U.S.), AbbVie Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (U.K.), CELGENE CORPORATION (U.S.), Leukemia Therapeutics, LLC (U.S.), Rasna Therapeutics, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Leukemia is a kind of blood cancer that affects both adults and children. The mutated genes lead to the growth of abnormal white blood cells present in the bone marrow and further lead to leukemia. Leukemia therapies involve the type of drugs used to treat this disease. There are varied treatment drugs that can help treat leukemia, such as targeted therapy, immunotherapy, and chemotherapy.
North America Leukemia Therapeutics Market Dynamics
Drivers
- Increasing R&D Activities Associated with Leukemia
The global market development is expected to be boosted by the R&D and new product launches being carried out by many companies. For instance, the National Cancer Institute (NCI) and Mayo Clinic will begin working together on a phase I trial in 2022 to evaluate the safety, effectiveness, and best dosage of onvansertib for treating patients suffering from relapsed or unresponsive chronic leukemia. Onvansertib interacts with and inhibits the PLK1 enzyme, which restricts the growth of cancer cells and leads to cell death. Such product development efforts and product launches are helping the market's growth. This factor boosts the market growth.
- Rise in Ageing Population
The elderly population is expected to increase rapidly in this region, which will boost the market in 2023-2030. As per the U.S. Census Bureau, more than 54 million adults aged 65 years and above live in the United States, resulting in about 16.5% of the nation's population. This increasing population has higher chances of leukemia; thus, the types of therapeutics are also increasing. This factor will increase the demand for the treatment processes. This boosts market growth.
Opportunities
- Increase in Usage in Hospitals
Hospitals and specialty clinics are the biggest end user of the leukemia therapeutics market and are growing due to the development of more and more hospitals. In addition, healthcare market players are also launching new and improved formulations of drugs for decreasing basal cell carcinoma cases. Thus, this factor will lead the market growth.
- Increased Demand for Chemotherapy
Chemotherapy is most often used for treating cancer as cancer cells grow and multiply much more quickly than most cells in the body. Chemotherapy is considered the standard treatment option for most individuals with leukemia. For instance, BDR Pharma launched India's first generic, Midostaurin, under the brand name MSTARIN in 2021. Midostaurin is a single-agent maintenance therapy for adults with newly diagnosed leukemia who are FLT3 mutation-positive. Thus, this factor increases the market growth.
Restraints/Challenges
- High Expenditure on Treatment
The high expenditure on treatment methods hinders the market growth. Moreover, per the article published by the American Society of Clinical Oncology Journal in 2020, the total annualized costs for leukemia were about US$ 82,054, more than those for hematologic malignancies (HEM) US$ 74,993 in the U.S. Thus, this factor hampers the market growth.
This leukemia therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the leukemia therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2022, the U.S. FDA approved quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation. It is used for the treatment of newly diagnosed adult patients with FLT3-ITD–positive AML.
North America Leukemia Therapeutics Market Scope
The leukemia therapeutics market is segmented on the basis of type, treatment type, molecule type, mode of administration, gender, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Acute Lymphocytic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
- Acute myeloid leukemia (AML)
- Chronic myeloid leukemia (CML)
- Others
Treatment Type
- Targeted Therapy
- Chemotherapy
- Cytarabine
- Anthracycline Drugs
- Alkylating Agents
- Anti-metabolites
- Tyrosine Kinase Inhibitors
- Immunotherapy
- Hormone Therapy
- Others
Molecule Type
- Small Molecules
- Biologics
Route of Administration
- Oral
- Parenteral
- Others
Gender
- Male
- Female
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Leukemia Therapeutics Market Regional Analysis/Insights
The leukemia therapeutics market is analyzed and market size insights and trends are provided by type, treatment type, molecule type, mode of administration, gender, end-users and distribution channel as referenced above.
The major countries covered in the leukemia therapeutics market report are the U.S., Canada and Mexico.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of north america brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Leukemia Therapeutics Market Share Analysis
The leukemia therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, north america presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to leukemia therapeutics market.
Key players operating in the leukemia therapeutics market include:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Cipla Inc. (U.S.
- Abbott (U.S.)
- AbbVie Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (U.K.)
- CELGENE CORPORATION (U.S.)
- Leukemia Therapeutics, LLC (U.S.)
- Rasna Therapeutics, Inc. (U.S.)
SKU-